Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients

被引:17
作者
Wang, Shun [1 ,2 ]
Hao, Mengqian [1 ,2 ]
Pan, Zishu [3 ]
Lei, Jinzhi [4 ]
Zou, Xiufen [1 ,2 ]
机构
[1] Wuhan Univ, Sch Math & Stat, Wuhan, Peoples R China
[2] Wuhan Univ, Hubei Key Lab Computat Sci, Wuhan, Peoples R China
[3] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan, Peoples R China
[4] Tiangong Univ, Ctr Appl Math, Sch Math Sci, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
CYTOKINE STORM; CELL; SNAPSHOT; TRANSMISSION; CORONAVIRUS; IMMUNITY;
D O I
10.1371/journal.pcbi.1009587
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Patients with coronavirus disease 2019 (COVID-19) often exhibit diverse disease progressions associated with various infectious ability, symptoms, and clinical treatments. To systematically and thoroughly understand the heterogeneous progression of COVID-19, we developed a multi-scale computational model to quantitatively understand the heterogeneous progression of COVID-19 patients infected with severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2). The model consists of intracellular viral dynamics, multicellular infection process, and immune responses, and was formulated using a combination of differential equations and stochastic modeling. By integrating multi-source clinical data with model analysis, we quantified individual heterogeneity using two indexes, i.e., the ratio of infected cells and incubation period. Specifically, our simulations revealed that increasing the host antiviral state or virus induced type I interferon (IFN) production rate can prolong the incubation period and postpone the transition from asymptomatic to symptomatic outcomes. We further identified the threshold dynamics of T cell exhaustion in the transition between mild-moderate and severe symptoms, and that patients with severe symptoms exhibited a lack of naive T cells at a late stage. In addition, we quantified the efficacy of treating COVID-19 patients and investigated the effects of various therapeutic strategies. Simulations results suggested that single antiviral therapy is sufficient for moderate patients, while combination therapies and prevention of T cell exhaustion are needed for severe patients. These results highlight the critical roles of IFN and T cell responses in regulating the stage transition during COVID-19 progression. Our study reveals a quantitative relationship underpinning the heterogeneity of transition stage during COVID-19 progression and can provide a potential guidance for personalized therapy in COVID-19 patients. Author summary Coronavirus disease 2019 (COVID-19) is currently destroying both lives and economies. However, patients infected with severe acute respiratory syndrome (SARS)-like coronavirus (SARS-CoV-2) usually present heterogeneous and complicated progressions, such as different incubation periods (short and long), symptoms (asymptomatic and symptomatic) and severity (mild-moderate and severe). Currently, various clinical data and experimental data are available from different countries, which has great significance for integrating different types of data to comprehensively understand the diverse disease progression in COVID-19 patients and guide individual treatment strategies. Here, we developed a multi-scale computational model to describe the dynamical process of patients infected with SARS-CoV-2, including intracellular viral dynamics, multicellular infection process, and immune responses. By combining data integration, stochastic simulation and quantitative analysis based on the multi-scale mathematical model, we addressed an important question regarding how IFN response and T cell exhaustion quantitatively affect heterogeneous progression in patients with respect to incubation periods, symptoms and severity. Furthermore, the efficacy of various therapeutic strategies for treating COVID-19 patients with different severity degrees was evaluated and validated. The computational framework in this study can also be extended to explore the dynamical process of other coronavirus infections.
引用
收藏
页数:28
相关论文
共 50 条
[41]   The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients [J].
Chen, Yifei ;
Chen, Liangjun ;
Deng, Qiaoling ;
Zhang, Guqin ;
Wu, Kaisong ;
Ni, Lan ;
Yang, Yibin ;
Liu, Bing ;
Wang, Wei ;
Wei, Chaojie ;
Yang, Jiong ;
Ye, Guangming ;
Cheng, Zhenshun .
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (07) :833-840
[42]   SARS-CoV-2 is not found in the sweat of COVID-19 positive patients [J].
Bengi Arslan ;
Sami Bercin ;
Sibel Aydogan ;
Yuce Islamoglu ;
Bedia Dinc .
Irish Journal of Medical Science (1971 -), 2022, 191 :27-29
[43]   SARS-Cov-2 Infection and Pulmonary Thromboembolism - The Prothrombotic State in COVID-19 [J].
Passos, Hellen Dutra ;
Alves, Mariana Carvalho ;
Baumworcel, Leonardo ;
Cerqueira Vieira, Joao Paulo ;
Seabra Garcez, Juliane Dantas ;
Sobral Sousa, Antonio Carlos .
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2020, 115 (01) :142-145
[44]   SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review [J].
Narang, Kavita ;
Enninga, Elizabeth Ann L. ;
Gunaratne, Madugodaralalage D. S. K. ;
Ibirogba, Eniola R. ;
Trad, Ayssa Teles A. ;
Elrefaei, Amro ;
Theiler, Regan N. ;
Ruano, Rodrigo ;
Szymanski, Linda M. ;
Chakraborty, Rana ;
Garovic, Vesna D. .
MAYO CLINIC PROCEEDINGS, 2020, 95 (08) :1750-1765
[45]   Correlates of protection against SARS-CoV-2 infection and COVID-19 disease [J].
Goldblatt, David ;
Alter, Galit ;
Crotty, Shane ;
Plotkin, Stanley A. .
IMMUNOLOGICAL REVIEWS, 2022, 310 (01) :6-26
[46]   SARS-CoV-2 Is Present in Peritoneal Fluid in COVID-19 Patients [J].
Coccolini, Federico ;
Tartaglia, Dario ;
Puglisi, Adolfo ;
Giordano, Cesira ;
Pistello, Mauro ;
Lodato, Marianna ;
Chiarugi, Massimo .
ANNALS OF SURGERY, 2020, 272 (03) :E240-E242
[47]   Assessment of SARS-CoV-2 Infection among Healthcare Workers of a German COVID-19 Treatment Center [J].
Larribere, Lionel ;
Gordejeva, Jelizaveta ;
Kuhnhenn, Lisa ;
Kurscheidt, Maximilian ;
Pobiruchin, Monika ;
Vladimirova, Dilyana ;
Martin, Maria ;
Roser, Markus ;
Schramm, Wendelin ;
Martens, Uwe M. ;
Eigenbrod, Tatjana .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (13)
[48]   COVID-19 Therapeutics: An Update on Effective Treatments Against Infection With SARS-CoV-2 Variants [J].
Padasas, Bill Thaddeus ;
Espano, Erica ;
Kim, Sang-Hyun ;
Song, Youngcheon ;
Lee, Chong-Kil ;
Kim, Jeong-Ki .
IMMUNE NETWORK, 2023, 23 (02)
[49]   The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19) [J].
Tauber, Amanda L. ;
Schweiker, Stephanie S. ;
Levonis, Stephan M. .
FUTURE MEDICINAL CHEMISTRY, 2021, 13 (06) :587-592
[50]   Modeling of COVID-19 disease disparity in gastric organoids reveals the spatiotemporal dynamics of SARS-CoV-2 infectivity [J].
Wang, Wenwen ;
Yang, Fengrui ;
Lin, Jie ;
Muthusamy, Saravanakumar ;
Du, Shihao ;
Mullen, McKay ;
Garba, Fatima ;
Wang, Wanjuan ;
Liu, Xu ;
Li, Tao ;
Yang, Zhihong ;
Ding, Xia ;
Aikhionbare, Felix ;
Gao, Xinjiao ;
Wang, Zhikai ;
Liu, Xing ;
Yao, Xuebiao .
JOURNAL OF MOLECULAR CELL BIOLOGY, 2022, 14 (02)